Dan Benjamin, Co-Founder & Chief Technology Officer of Immuto Scientific, examines why limited antibody–antigen co-structure datasets may be constraining AI model performance—and how high-throughput structural generation could reshape the field. Artificial intelligence now plays a central role in antibody discovery. Machine learning models assist in sequence design, paratope prediction, affinity maturation, and developability screening. Yet […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!